We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
DiaMedica Therapeutics Inc | NASDAQ:DMAC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.37 | 14.07% | 3.00 | 3.00 | 3.25 | 3.05 | 2.65 | 2.65 | 102,677 | 01:00:00 |
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.
Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005660/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com
1 Year DiaMedica Therapeutics Chart |
1 Month DiaMedica Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions